Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study.
The study suggests that combining injectable platelet-rich fibrin with bioactive peptides may enhance dermal fibroblast viability and gene expression, but further research is needed to confirm these effects in clinical settings.
Where it sits
this study against the rest of the matrixyl corpusSummary and findings
This in vitro study assessed the effects of injectable platelet-rich fibrin (i-PRF) combined with bioactive peptides Matrixyl and GEKG on human dermal fibroblast viability and extracellular matrix gene expression. The study found that combinations, particularly i-PRF + GEKG, increased cell viability and upregulated ECM-related genes at 72 hours. No therapeutic claims are made.
Abstract
Facial aging is a multifactorial process involving changes in bone, fat compartments, ligaments, muscles, and skin. Collagen biostimulators, including synthetic agents and autologous platelet concentrates, have gained attention for facial rejuvenation. Injectable platelet-rich fibrin (i-PRF), a second-generation autologous concentrate, has shown promising regenerative properties due to its natural composition and growth factors. Cosmetic peptides, such as palmitoyl pentapeptide-4 (Matrixyl) and Tetrapeptide-21 (GEKG), are also studied for their ability to stimulate collagen synthesis and remodel the extracellular matrix. This in vitro study examined the potential synergistic effects of i-PRF combined with Matrixyl or GEKG on human dermal fibroblast viability, proliferation, and ECM-related gene expression. Fibroblasts were cultured under six conditions: control, i-PRF alone, Matrixyl alone, GEKG alone, i-PRF + Matrixyl, and i-PRF + GEKG. Viability and proliferation were assessed via MTT, crystal violet, and RealTime-Glo™ assays. Gene expression of <i>COL1A1</i>, <i>FN1</i>, and <i>HAS1</i> was measured using RT-qPCR. The combinations, especially i-PRF + GEKG, led to increased cell viability and upregulated ECM-related genes at 72 h. These effects were stronger than the individual treatments, suggesting synergistic effects, especially with GEKG. These findings highlight the clinical potential of combining autologous platelet concentrates with bioactive peptides for dermal regeneration. Further preclinical and clinical studies are warranted.
Background
The study addresses the biological question of how injectable platelet-rich fibrin and bioactive peptides influence dermal fibroblast viability and extracellular matrix gene expression. Previous research has indicated that both platelet-rich fibrin and bioactive peptides can play roles in skin regeneration, but their synergistic effects have not been thoroughly explored. Understanding these interactions is important for potential applications in dermatology and regenerative medicine.
Methods
This study employed an in vitro design to assess the effects of injectable platelet-rich fibrin and bioactive peptides on dermal fibroblasts. The specific population or model used, sample size (n), doses, and duration of treatment were not reported in the abstract. Primary and secondary outcome measures related to fibroblast viability and gene expression were evaluated.
Results
Not reported in abstract.
Interpretation
The findings of this study, while potentially informative, cannot be compared to prior literature due to the lack of reported results. Without specific numeric findings or effect sizes, it is unclear whether any observed effects would be clinically meaningful. Limitations such as the in vitro nature of the study and potential confounds from the experimental design may restrict the applicability of the results to clinical practice.
Key findings
- Not reported in abstract.
Limitations
- Not reported in abstract.